Eleven Biotherapeutics Inc. (EBIO) Trading 12.9% Higher
Shares of Eleven Biotherapeutics Inc. (NASDAQ:EBIO) traded up 12.9% during mid-day trading on Friday . The company traded as high as $4.87 and last traded at $4.55, with a volume of 5,339,037 shares. The stock had previously closed at $4.03.
The stock’s market cap is $71.88 million. The stock has a 50 day moving average price of $2.92 and a 200 day moving average price of $1.33.
Eleven Biotherapeutics (NASDAQ:EBIO) last issued its quarterly earnings data on Friday, August 12th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter. On average, analysts anticipate that Eleven Biotherapeutics Inc. will post ($1.75) EPS for the current fiscal year.
In other news, major shareholder Boxer Capital, Llc sold 1,042,000 shares of the business’s stock in a transaction that occurred on Monday, June 13th. The shares were sold at an average price of $2.74, for a total transaction of $2,855,080.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Eleven Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company through AMP-Rx, a protein engineering platform, is engaged in the discovery and development of protein therapeutics to treat diseases of the eye. The Company designs, engineers and generates a pipeline of protein therapeutic candidates that target cytokines, which are central to diseases of the eye.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.